[1] Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015[J].CA Cancer J Clin，2016,66(2):115-132.[2] Zazove P，Reed BD，Gregoire L，et al.Low false-negative rate of PCR analysis for detecting human papillomavirus-related cervical lesions[J].J Clin Microbiol，1998，36（9）：2708-2713.[3] Nanda K，McCrory DC，Myers ER，et al.Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities：a systematic review[J].Annals Int Med，2000，132（10）：810-819.[4] Katki HA，Kinney WK，Fetterman K.Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology：a population-based study in routine clinical practice[J].Lancet Oncol，2011，12（8）：722-728.[5] Castle PE，Glass AG，Rush BB，et al.Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up[J].J Clin Oncol，2012，30（25）：3044-3050.[6] Smith RA，Manassaram-Baptiste D，Brooks D，et al.Cancer screening in the United States，2015：a review of current American cancer society guidelines and current issues in cancer screening[J].CA Cancer J Clin，2015，65（1）：30-54.[7] Wentzensen N，Fetterman B，Castle PE，et al.p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women[J].J Natl Cancer Inst，2015，107（12）：257-261.[8] Przybycin CG, Kurman RJ, Ronnett BM，et al.Are All pelvic (nonuterine)erous carcinomas of tubal origin?[J].Am J Surg Pathol, 2010，34（10）：1407-1416.[9] Kurman RJ，Shih IM.Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm[J].Hum Pathol，2011，42（7）：918-931.[10] Cancer Genome Atlas Research.Integrated genomic analyses of ovarian carcinoma[J].Nature，2011，474（7353）：609-615.[11] Rubin SC，Blackwood MA，Bandera C，et al.BRCA1，BRCA2，and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population：relationship to family history and implications for genetic testing[J].Am J Obstet Gynecol，1998，178（4）：670-677.[12] Kauff ND，Satagopan JM，Robson ME，et al.Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation[J].New Engl J Med，2002，346（21）：1609-1615.[13] Lheureux S，Shaw PA，Karakasis K，et al.Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy：accuracy of assessment and potential surrogate marker for prevention[J].Gynecol Oncol，2015，138（2）：235-237.[14] Barton CA，Hacker NF，Clark SJ，et al.DNA methylation changes in ovarian cancer：implications for early diagnosis，prognosis and treatment[J].Gynecol Oncol，2008，109（1）：129-139.[15] de Caceres II，Battagli C，Esteller M，et al.Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum，plasma，and peritoneal fluid from ovarian cancer patients[J].Cancer Res，2004，64（18）：6476-6481.[16] Collins Y，Dicioccio R，Keitz B，et al.Methylation of death-associated protein kinase in ovarian carcinomas[J].Int J Gynecol Cancer，2006，16：195-199.[17] Liu B，Parsons R，Papadopoulos N，et al.Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients[J].Nature Med，1996，2（2）：169-174.[18] Boland CR.A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition：development of international criteria for the determination of microsatellite instability in colorectal cancer[J].Cancer Res，1999，59（1）：249-256.[19] Karlan BY，Berchuck A，Mutch D.The role of genetic testing for cancer susceptibility in gynecologic practice[J].Obstet Gynecol，2007，110（1）：155-167.[20] Dove-Edwin I，Boks D，Goff S，et al.The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma[J].Cancer，2002，94（6）：1708-1712.（2016-02-25收稿）
